- Report
- January 2024
- 269 Pages
Global
From €6560EUR$7,077USD£5,481GBP
- Report
- January 2024
- 144 Pages
Global
From €3741EUR$3,899USD£3,235GBP
- Report
- June 2023
- 83 Pages
Global
From €3500EUR$3,908USD£3,132GBP
- Report
- October 2023
- 270 Pages
China
From €3838EUR$4,000USD£3,319GBP
- Report
- October 2023
- 135 Pages
China
From €1727EUR$1,800USD£1,493GBP
Cefotaxime is a third-generation cephalosporin antibiotic used to treat a wide range of bacterial infections. It is commonly used to treat infections of the respiratory tract, urinary tract, skin, and soft tissue. Cefotaxime is also used to treat meningitis, septicemia, and endocarditis. It is effective against both Gram-positive and Gram-negative bacteria. Cefotaxime is available in both intravenous and intramuscular forms.
Cefotaxime is part of the larger market of antibiotics, which are used to treat bacterial infections. Antibiotics are a major component of modern medicine, and are used to treat a wide range of bacterial infections. The market for antibiotics is highly competitive, with many different companies offering a variety of products.
Some of the companies in the Cefotaxime market include Pfizer, Merck, GlaxoSmithKline, Sanofi, and AstraZeneca. Show Less Read more